Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Sell Bank of America Corp (BAC) Stock and Buy THIS Bank Instead

Bank of America Corp (NYSE:BAC) has had a great 2016, but as we roll into 2017, the risk of a sector correction looms large.

It’s Time for Facebook Inc (FB) to Start Paying a Dividend

An interesting pattern is developing with Facebook Inc (NASDAQ:FB) stock that suggests now is the time to introduce a dividend. 

Is Ford Motor Company (F) Stock a Good Value?

Ford (F) looks appealing in several aspects, but the question is whether Ford stock holds up for true value investors.

General Electric Company (GE): Good Company, Terrible Stock

With Jeffrey Immelt in his 16th year as General Electric Company CEO, GE stock is one of the biggest disappoints on the Dow.

Trump Is Doing Exxon Mobil Corporation (XOM) Stock a YUGE Favor

Love or hate the appointment, Exxon Mobil shareholders should be jumping for joy. Under Tillerson’s leadership, XOM stock has gone to the dogs.

3 Reasons Why Alphabet Inc (GOOGL) Stock Is a Must-Own for 2017

Yes, Alphabet (GOOGL) has underperformed the market in 2016. But from here, avoiding GOOGL stock is a lost opportunity.

Bank Stocks: 5 of the Best Canadian Stocks to Buy

Despite their stellar returns in 2016, Canadian banks remain some of the best Canadian stocks to buy heading into 2017.

Does Tesla Motors Inc (TSLA) Stock Belong in Your IRA?

Tesla Motors (TSLA) is a brilliant company, and Elon Musk will make America great again. But is Tesla stock a retirement holding?

Value Battle: Pfizer Inc. (PFE) vs. Merck & Co., Inc. (MRK)

Pfizer (PFE) hasn't done very well in 2016, making its value battle with Merck (MRK) an interesting proposition.  

The 10 Biggest Stock Market Failures of 2016 

There weren’t too many stock market horror stories in 2016 but these 10 stocks definitely had a hard time winning investors’ affections.